ZURA BIO LIMITED Cash and Restricted Cash
ZURA BIO LIMITED (ZURA) had Cash and Restricted Cash of $205.13 thousand as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-11
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $205.13K.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $225.59M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $109.41K; Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed $109.41M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $139.02M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $205.13K 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $225.59M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $109.41K 10-Q · filed 2026-08-11 | $109.41M 10-K · filed 2026-03-19 |
| 2025-09-30 | $139.02M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $154.49K 10-Q · filed 2026-08-11 | $154.49M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $170.57M 10-Q · filed 2026-05-07 | |
| 2024-12-31 | $176.50K 10-Q · filed 2026-08-11 | $176.50M 10-K · filed 2025-03-25 |
| 2024-09-30 | $188.22M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $188.44M 10-Q · filed 2025-08-14 | |
| 2024-03-31 | $89.82M 10-Q · filed 2025-05-08 | |
| 2023-12-31 | $99.81M 10-K · filed 2026-03-19 | |
| 2023-09-30 | $103.86M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $112.80M 10-Q · filed 2024-08-13 | |
| 2023-03-31 | $43.96M 10-Q · filed 2024-05-09 | |
| 2022-12-31 | $1.57M 10-K · filed 2025-03-25 | $13.79K 10-K · filed 2023-03-28 |
| 2022-09-30 | $3.05M 10-Q · filed 2023-11-13 | $74.45K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $4.41M 10-Q · filed 2023-08-14 | $220.74K 10-Q · filed 2022-08-12 |
| 2022-03-31 | $4.72M 10-Q · filed 2023-05-12 | $514.60K 10-Q · filed 2022-05-13 |
| 2021-12-31 | $729.22K 10-K · filed 2023-03-28 | |
| 2021-09-30 | $986.65K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $24.98K 10-Q · filed 2022-08-12 | |
| 2021-03-31 | $24.98K 10-Q · filed 2021-08-27 | |
| 2021-03-09 | $0.00 10-K · filed 2023-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |